FDA approval of gilteritinib in 2018 for the treatment of R/R AML FLT3 patients was based on ADMIRAL trial (NCT02421939) which reported higher CR and OS rates compared to salvage chemotherapy. Here, FLT3 is linked to acute myeloid leukemia.